Cite
Real World Evidence and Clinical Utility of KidneyIntelX on Patients With Early-Stage Diabetic Kidney Disease: Interim Results on Decision Impact and Outcomes.
MLA
Tokita, Joji, et al. “Real World Evidence and Clinical Utility of KidneyIntelX on Patients With Early-Stage Diabetic Kidney Disease: Interim Results on Decision Impact and Outcomes.” Journal of Primary Care & Community Health, Nov. 2022, pp. 1–9. EBSCOhost, https://doi.org/10.1177/21501319221138196.
APA
Tokita, J., Vega, A., Sinfield, C., Naik, N., Rathi, S., Martin, S., Wang, S., Amoruso, L., Zabetian, A., Coca, S. G., Nadkarni, G. N., Fleming, F., Donovan, M. J., & Fields, R. (2022). Real World Evidence and Clinical Utility of KidneyIntelX on Patients With Early-Stage Diabetic Kidney Disease: Interim Results on Decision Impact and Outcomes. Journal of Primary Care & Community Health, 1–9. https://doi.org/10.1177/21501319221138196
Chicago
Tokita, Joji, Aida Vega, Catherine Sinfield, Nidhi Naik, Shivani Rathi, Sharlene Martin, Stephanie Wang, et al. 2022. “Real World Evidence and Clinical Utility of KidneyIntelX on Patients With Early-Stage Diabetic Kidney Disease: Interim Results on Decision Impact and Outcomes.” Journal of Primary Care & Community Health, November, 1–9. doi:10.1177/21501319221138196.